PayPal vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Jose digital payments platform (NASDAQ: PYPL) at $31.8B 2024 revenue processing $1.68T volume across 434M accounts; CEO Chriss AI personalization strategy with Fastlane checkout competing with Stripe and Apple Pay for digital commerce.
About
PayPal Holdings is a San Jose, California-based digital payments technology platform — publicly traded on NASDAQ (NASDAQ: PYPL) at approximately $70 billion market capitalization — providing 434 million active accounts across 200+ markets with digital wallet services (PayPal consumer, Venmo P2P payments), merchant payment processing (PayPal Checkout, Braintree enterprise processing), and buy now pay later (Pay Later). In 2024, PayPal processed $1.68 trillion in total payment volume across 26.3 billion transactions, reporting $31.8 billion in revenue (7% year-over-year growth) and $6.8 billion in free cash flow — with the board authorizing a new $15 billion share repurchase program. Under CEO Alex Chriss (since September 2023), PayPal launched Fastlane (accelerated guest checkout), AI-powered merchant personalization, and PayPal Everywhere (debit card rewards) as new revenue initiatives. Founded in 1998 (as Confinity), spinoff from eBay in 2015.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.